Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 3
2011 4
2012 9
2013 13
2014 7
2015 7
2016 8
2017 7
2018 8
2019 3
2020 4
2021 1
Text availability
Article attribute
Article type
Publication date

Search Results

62 results
Results by year
Filters applied: . Clear all
Page 1
GPCR-specific autoantibody signatures are associated with physiological and pathological immune homeostasis.
Cabral-Marques O, Marques A, Giil LM, De Vito R, Rademacher J, Günther J, Lange T, Humrich JY, Klapa S, Schinke S, Schimke LF, Marschner G, Pitann S, Adler S, Dechend R, Müller DN, Braicu I, Sehouli J, Schulze-Forster K, Trippel T, Scheibenbogen C, Staff A, Mertens PR, Löbel M, Mastroianni J, Plattfaut C, Gieseler F, Dragun D, Engelhardt BE, Fernandez-Cabezudo MJ, Ochs HD, Al-Ramadi BK, Lamprecht P, Mueller A, Heidecke H, Riemekasten G. Cabral-Marques O, et al. Among authors: braicu i. Nat Commun. 2018 Dec 6;9(1):5224. doi: 10.1038/s41467-018-07598-9. Nat Commun. 2018. PMID: 30523250 Free PMC article.
miR-181a overexpression predicts the poor treatment response and early-progression of serous ovarian cancer patients.
Panoutsopoulou K, Avgeris M, Magkou P, Mavridis K, Dreyer T, Dorn J, Obermayr E, Reinthaller A, Michaelidou K, Mahner S, Vergote I, Loverix L, Braicu I, Sehouli J, Zeillinger R, Magdolen V, Scorilas A. Panoutsopoulou K, et al. Among authors: braicu i. Int J Cancer. 2020 Dec 15;147(12):3560-3573. doi: 10.1002/ijc.33182. Epub 2020 Aug 1. Int J Cancer. 2020. PMID: 32621752
miR-203 is an independent molecular predictor of prognosis and treatment outcome in ovarian cancer: a multi-institutional study.
Panoutsopoulou K, Avgeris M, Mavridis K, Dreyer T, Dorn J, Obermayr E, Reinthaller A, Michaelidou K, Mahner S, Vergote I, Vanderstichele A, Braicu I, Sehouli J, Zeillinger R, Magdolen V, Scorilas A. Panoutsopoulou K, et al. Among authors: braicu i. Carcinogenesis. 2020 Jun 17;41(4):442-451. doi: 10.1093/carcin/bgz163. Carcinogenesis. 2020. PMID: 31586203
Part I of GANNET53: A European Multicenter Phase I/II Trial of the Hsp90 Inhibitor Ganetespib Combined With Weekly Paclitaxel in Women With High-Grade, Platinum-Resistant Epithelial Ovarian Cancer-A Study of the GANNET53 Consortium.
Ray-Coquard I, Braicu I, Berger R, Mahner S, Sehouli J, Pujade-Lauraine E, Cassier PA, Moll UM, Ulmer H, Leunen K, Zeimet AG, Marth C, Vergote I, Concin N. Ray-Coquard I, et al. Among authors: braicu i. Front Oncol. 2019 Sep 10;9:832. doi: 10.3389/fonc.2019.00832. eCollection 2019. Front Oncol. 2019. PMID: 31552170 Free PMC article.
Dynamics of the Intratumoral Immune Response during Progression of High-Grade Serous Ovarian Cancer.
Stanske M, Wienert S, Castillo-Tong DC, Kreuzinger C, Vergote I, Lambrechts S, Gabra H, Gourley C, Ganapathi RN, Kolaschinski I, Budczies J, Sehouli J, Ruscito I, Denkert C, Kulbe H, Schmitt W, Jöhrens K, Braicu I, Darb-Esfahani S. Stanske M, et al. Among authors: braicu i. Neoplasia. 2018 Mar;20(3):280-288. doi: 10.1016/j.neo.2018.01.007. Epub 2018 Feb 22. Neoplasia. 2018. PMID: 29466768 Free PMC article.
62 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page